OCT 5 1602

APPENDIX A NOTICE OF VIOLATION

Paul H. Pevsner, M.D. Washington, D.C. 20037

Docket No. 30-19490 License No. 08-19896-01

As a result of the inspection conducted on August 15, 1982, and in accordance with the NRC Enforcement Policy (10 CFR 2, Appendix C), the following violations were identified:

A. 10 CFR 19.12 requires that all individuals working in restricted areas be instructed in the applicable provisions of the Commission's regulations and licenses.

Contrary to the above, as of August 16, 1982, individuals who were working in the restricted area had not been instructed in the applicable provisions of the regulations and the specific conditions of the license.

This is a Severity Level IV violation (Supplement VI).

- B. Condition 13 of License No. 09-19896-01 requires that licensed material be possessed and used in accordance with statements, representations and procedures contained in application dated October 1, 1981.
 - Item 15 of this application requires that patient doses containing radioactive material be prepared and administered using lead syringe shields.

Contrary to the above, as of August 16, 1982, personnel failed to use syringe shields during the administration of patient doses containing radioactive material.

This is a Severity Level IV violation (Supplement VI).

Item 24 of this application requires that exposures to the extremities of personnel be evaluated by the use of finger ring badges.

Contrary to the above, as of August 16, 1982, finger ring badges had not been assigned to evaluate the dose to the extremities of technicians administering radiopharmaceuticals.

This is a Severity Level IV violation (Supplement IV).

Pursuant to the provisions of 10 CFR 2.201, Paul H. Pevsner, M.D. is hereby required to submit to this office within thirty days of the date of this Notice, a written statement or explanation in reply, including: (1) the corrective steps which have been taken and the results achieved; (2) corrective steps which will be taken to avoid further violations; and (3) the date when full compliance will be achieved. Where good cause is shown, consideration will be given to extending this response time.